Allogene Therapeutics, Inc. (ALLO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic ("off-the-shelf") T cell product candidates for cancer and autoimmune diseases. The company is currently focused on three core clinical programs: ALPHA3 (cema-cel for large B-cell lymphoma), TRAVERSE (ALLO-316 for renal cell carcinoma), and RESOLUTION (ALLO-329 for autoimmune diseases).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $22,000 |
| Net Loss | $(50.9) million | $(66.4) million | $(110.7) million | $(131.4) million |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.35) | $(0.51) | $(0.73) |
| Operating Expenses | $56.8 million | $71.4 million | $122.0 million | $141.0 million |
| Cash & Investments | $302.6 million (as of June 30, 2025) | |||
| Cash Used in Operating Activities (YTD) | $(92.0) million | $(119.5) million |
Note: All figures in millions unless otherwise noted.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 20% in Q2 2025 compared to Q2 2024, driven by a 28% workforce reduction initiated in May 2025 and reduced manufacturing operations.
- Impairment Charges: The company recorded $2.4 million in impairment of long-lived assets for Q2 2025, compared to $5.0 million in Q2 2024. The 2025 charge included $1.0 million related to a subleased building and $1.3 million in equipment impairment due to the workforce reduction.
- Workforce Reduction Costs: Approximately $3.1 million in severance and benefits were recorded in Q2 2025 expenses.
- Interest Income: Interest and other income increased to $6.2 million in Q2 2025 from $5.0 million in Q2 2024, aided by sublease income and foreign exchange gains.
Guidance, Outlook, and Management Commentary
- Clinical Trial Update (ALPHA3): On August 1, 2025, the company announced the closure of the FCA arm (fludarabine, cyclophosphamide, and ALLO-647) of the ALPHA3 trial following a Grade 5 adverse event (hepatic failure) attributed to ALLO-647. The trial will proceed as a randomized study comparing cema-cel with standard FC lymphodepletion against observation. The next milestone (futility analysis) is expected in the first half of 2026.
- Capital Runway: Management expects cash, cash equivalents, and investments of $302.6 million to fund operations into the second half of 2027.
- Strategic Focus: The company is reprioritizing resources to focus on clinical programs (ALPHA3, RESOLUTION, TRAVERSE) and has reduced manufacturing operations. It is advancing next-generation products using the Dagger Platform Technology to minimize the need for standard lymphodepletion.
- Financing: The company raised $11.5 million in net proceeds from ATM offerings during the six months ended June 30, 2025.
Investor Verification Checklist
- ALPHA3 Trial Viability: Verify the impact of removing the ALLO-647 arm on the trial's statistical power and the efficacy of the standard FC lymphodepletion regimen alone.
- Manufacturing Capacity: Assess the risks associated with the 28% workforce reduction and reduced manufacturing operations on the ability to supply clinical trials and potential future commercialization.
- Intellectual Property Risks: Monitor the ongoing arbitration between Cellectis and Servier, which could impact Allogene's access to TALEN gene-editing technology required for its oncology products.
- Companion Diagnostic: Confirm the regulatory status and reliability of the Foresight Diagnostics MRD assay, which is critical for patient selection in the ALPHA3 trial.
- Cash Burn Rate: Track the quarterly cash burn rate to ensure the projected runway into late 2027 remains accurate given the scale-down in operations.